All conditions

Breast Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

21
Trials tracked
3
Recruiting now
19
Australian sites
59
Countries
Country

Showing 21 trials

🇦🇺 AU site

Trial: NCT05382286 — Gilead Sciences

NCT05382286 · Gilead Sciences
Active, Not Recruiting Phase 3 Est. completion 1 February 2027
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

Who might be able to join this trial: - You have triple-negative breast cancer (a specific type of breast cancer) that has spread or cannot be removed by surgery, and you have not yet received any systemic (whole-body) treatment for this ad...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT04556773 — AstraZeneca

NCT04556773 · AstraZeneca
Active, Not Recruiting Phase 1 Est. completion 16 August 2023
🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA 🇫🇷 FR

**Who might be able to join this trial:** - You must be at least 18 years old - You must have been diagnosed with breast cancer that has been confirmed by a lab test to show a certain low level of a protein called HER2 (measured as IHC 2+/I...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT04191499 — Hoffmann-La Roche

NCT04191499 · Hoffmann-La Roche
Active, Not Recruiting Phase 3 Est. completion 29 September 2023
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with breast cancer that is hormone receptor-positive (HR+) and HER2-negative - Your cancer has spread to other parts of the body or is advanced in a way that cannot be cur...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT02246621 — Eli Lilly and Company

NCT02246621 · Eli Lilly and Company
Active, Not Recruiting Phase 3 Est. completion 31 January 2017
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇨🇦 CA 🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with a type of breast cancer that is hormone receptor-positive (HR+) and HER2-negative (HER2-) - Your breast cancer has either come back in the local area and cannot be ful...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT03701334 — Novartis Pharmaceuticals

NCT03701334 · Novartis Pharmaceuticals
Active, Not Recruiting Phase 3 Est. completion 29 May 2030
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You have signed and dated a consent form before any trial-related tests begin. - You are 18 years old or older when you sign the consent form. - You are either male, or a female with a known meno...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT02032823 — AstraZeneca

NCT02032823 · AstraZeneca
Active, Not Recruiting Phase 3 Est. completion 27 March 2020
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇨🇦 CA

Who might be able to join this trial: - You have been diagnosed with breast cancer that has not spread to other parts of the body, and the cancer has been confirmed by a tissue sample (biopsy). - Your breast cancer is either "triple negativ...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT02675231 — Eli Lilly and Company

NCT02675231 · Eli Lilly and Company
Completed Phase 2 Est. completion 8 April 2019
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with breast cancer that is both HR+ (hormone receptor-positive) and HER2+ (HER2-positive). - Your breast cancer cannot be removed by surgery, has come back locally, or has...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT02019277 — Hoffmann-La Roche

NCT02019277 · Hoffmann-La Roche
Completed Phase 3 Est. completion 4 November 2016
🇦🇺 AU

**Who might be able to join this trial:** - Your breast cancer tumor tests positive for a protein called HER2 (confirmed by lab testing of the tumor). - You have been diagnosed with breast cancer that has spread to other parts of the body...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT01075802 — Western Sydney Local Health District

NCT01075802 · Western Sydney Local Health District
Completed Not Applicable Est. completion 1 October 2012
🇦🇺 AU

**Who might be able to join this trial:** - You are generally able to carry out your normal daily activities with little or no limitation (confirm with trial site) - Your doctors expect you to live for at least 6 months or more - You have b...

Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT02437318 — Novartis Pharmaceuticals

NCT02437318 · Novartis Pharmaceuticals
Completed Phase 3 Est. completion 12 June 2018
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - If you are female, you must be postmenopausal. - Your cancer must have been tested to determine the status of a gene called PIK3CA. - You relapsed (cancer came back) with clear evidence it was gr...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT02273973 — Genentech, Inc.

NCT02273973 · Genentech, Inc.
Completed Phase 2 Est. completion 13 March 2017
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇨🇱 CL

**Who might be able to join this trial:** - You are female and have gone through menopause - You have been diagnosed with invasive breast cancer, confirmed by a tissue sample (biopsy) - Your tumor is at least 2 centimeters in size, measure...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT01958021 — Novartis Pharmaceuticals

NCT01958021 · Novartis Pharmaceuticals
Completed Phase 3 Est. completion 29 January 2016
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You are a woman with advanced breast cancer (either spread to other parts of the body, or returned in the local area) that cannot be cured. - You have gone through menopause — either naturally (b...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT00777101 — Puma Biotechnology, Inc.

NCT00777101 · Puma Biotechnology, Inc.
Completed Phase 2 Est. completion 1 March 2011
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇬 BG 🇨🇦 CA

Who might be able to join this trial: - You have been diagnosed with advanced or late-stage breast cancer (Stage IIIB, IIIC, or IV) that tests positive for a protein called HER2 (also written as erbB2) - You have previously been treated wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT02338245 — ASLAN Pharmaceuticals

NCT02338245 · ASLAN Pharmaceuticals
Completed Phase 2 Est. completion 19 May 2016
🇦🇺 AU Hong Kong 🇳🇿 NZ 🇵🇭 PH 🇸🇬 SG

**Who might be able to join this trial:** - You have been diagnosed with breast cancer that has been confirmed by a tissue sample (biopsy), and your cancer tests positive for a protein called HER2 (meaning HER2 is overexpressed or the gene...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT00082433 — R-Pharm

NCT00082433 · R-Pharm
Completed Phase 3 Est. completion 1 March 2008
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

Who might be able to join this trial: - You must have previously been treated with chemotherapy drugs from two specific groups: one called an anthracycline (such as doxorubicin or epirubicin) and one called a taxane (such as paclitaxel or d...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT06952803 — AstraZeneca

NCT06952803 · AstraZeneca
Recruiting Phase 3 Est. completion 31 March 2033
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You are male and have been diagnosed with prostate cancer (confirmed by a tissue sample/biopsy). - You have either newly diagnosed high-risk prostate cancer (cancer that has not spread far, but i...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT05508906 — Olema Pharmaceuticals, Inc.

NCT05508906 · Olema Pharmaceuticals, Inc.
Recruiting Phase 1 Est. completion 31 December 2027
🇦🇺 AU 🇺🇸 US

**Who might be able to join this trial:** - You are a male or female aged 18 or older - You are willing and able to follow all study requirements throughout the trial - Your breast cancer has been confirmed by a lab test (biopsy or cell sa...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT05774951 — AstraZeneca

NCT05774951 · AstraZeneca
Recruiting Phase 3 Est. completion 20 April 2027
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You are a man or woman aged 18 or older at the time of screening (or meet the age requirement based on your country's guidelines) - You have been diagnosed with a specific type of early-stage bre...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗
🇦🇺 AU site

Trial: NCT00373113 — Pfizer

NCT00373113 · Pfizer
Terminated Phase 3 Est. completion 1 October 2009
🇦🇷 AR 🇦🇺 AU 🇧🇷 BR 🇧🇬 BG 🇨🇦 CA

"Who might be able to join this trial: - You have been diagnosed with a type of breast cancer called breast adenocarcinoma - You have already been treated with two specific types of chemotherapy drugs — an anthracycline and a taxane — eithe...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗

Trial: NCT05545150 — Northwestern University

NCT05545150 · Northwestern University
Active, Not Recruiting Phase 2 Est. completion 26 July 2024
🇺🇸 US

Who might be able to join this trial: - You are a woman aged 18 or older who has been diagnosed with invasive breast cancer and/or a non-invasive breast condition called ductal carcinoma in situ (DCIS) - You are planning to have breast-cons...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗

Trial: NCT06504719 — Hellenic Cooperative Oncology Group

NCT06504719 · Hellenic Cooperative Oncology Group
Completed Not Applicable Est. completion 1 June 2024
🇬🇷 GR

**Who might be able to join this trial:** - You have been diagnosed with breast cancer that has spread to other parts of the body or has come back, confirmed by a tissue sample (biopsy). - You are 18 years of age or older. - Your breast can...

Data last synced from ClinicalTrials.gov: 30 June 2026
Read full eligibility ClinicalTrials.gov ↗